251 related articles for article (PubMed ID: 33169692)
21. Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.
Joshi SK; Qian K; Bisson WH; Watanabe-Smith K; Huang A; Bottomly D; Traer E; Tyner JW; McWeeney SK; Davare MA; Druker BJ; Tognon CE
Blood; 2020 Jun; 135(24):2159-2170. PubMed ID: 32315394
[TBL] [Abstract][Full Text] [Related]
22. Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services.
Walker A
J Oncol Pharm Pract; 2020 Dec; 26(8):2015-2019. PubMed ID: 32957860
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract][Full Text] [Related]
24. Revisiting NTRKs as an emerging oncogene in hematological malignancies.
Joshi SK; Davare MA; Druker BJ; Tognon CE
Leukemia; 2019 Nov; 33(11):2563-2574. PubMed ID: 31551508
[TBL] [Abstract][Full Text] [Related]
25. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
Laetsch TW
Clin Adv Hematol Oncol; 2024 May; 22 Suppl 3(4):1-11. PubMed ID: 38739704
[No Abstract] [Full Text] [Related]
26. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
27. Larotrectinib: First Global Approval.
Scott LJ
Drugs; 2019 Feb; 79(2):201-206. PubMed ID: 30635837
[TBL] [Abstract][Full Text] [Related]
28. TRK inhibitors in TRK fusion-positive cancers.
Drilon A
Ann Oncol; 2019 Nov; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
[TBL] [Abstract][Full Text] [Related]
29. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
30. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
31. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
32. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
[TBL] [Abstract][Full Text] [Related]
33. Site-agnostic biomarker-guided oncology drug development.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
[TBL] [Abstract][Full Text] [Related]
34. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
[TBL] [Abstract][Full Text] [Related]
35. How I treat
Lassen U
ESMO Open; 2019; 4(Suppl 2):e000612. PubMed ID: 31803506
[No Abstract] [Full Text] [Related]
36. Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
Carter-Febres M; Schneller N; Fair D; Solomon D; Perry A; Roy A; Linscott L; Alashari M; Kestle JR; Bruggers CS
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e987-e990. PubMed ID: 33093355
[TBL] [Abstract][Full Text] [Related]
37.
Pfaff E; Adam de Beaumais T; Marchais A; van Tilburg CM; Blattner-Johnson M; Dirksen U; Øra I; Geoerger B; Schleiermacher G; Pfister SM; Witt O; Jones DTW; Vassal G
JCO Precis Oncol; 2021 Nov; 5():450-454. PubMed ID: 34994601
[No Abstract] [Full Text] [Related]
38. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
Blauel ER; Laetsch TW
Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
[TBL] [Abstract][Full Text] [Related]
39. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
[TBL] [Abstract][Full Text] [Related]
40. On the right TRK: from oncogene discovery to cancer therapeutics.
Barbacid M
Ann Oncol; 2019 Nov; 30 Suppl 8(Suppl 8):viii3-viii4. PubMed ID: 32223936
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
